IGFBP5 and neoplasm: After normalization to anti-BSA levels, standardized ratios of anti-AGR2, anti-HAPLN1, anti-IGFBP5, and anti-TYMS were significantly higher in malignant and early-stage CMTs, suggesting selective amplification of tumor-specific immune responses despite global immune suppression.